Agent Potency Yield (APY)
Whether the compliance, sedation, and fertility agents are still doing what they were built to do.
Formula
Thresholds & Bands
| Band | Range | State |
|---|---|---|
| On-spec | ≥ 95 | ok |
| Degraded | 85-95 | warn |
| Off-spec | < 85 | crit |
Why This Metric Matters
Agent Potency Yield determines whether the Directorate's pharmacological control agents — compliance compounds, sedation agents, and fertility modulators (Fertilen/Fecundyne) — are performing at their designed efficacy when they reach the subject population. Potency degradation is insidious: it produces no acute failure signal, only a gradual erosion of population-level compliance, sentiment stability, and fertility management that may not surface in downstream metrics for weeks. By the time behavioral indicators shift, the Directorate has already lost ground that requires costly recalibration to recover. APY is the early-warning system that prevents that lag.
Threshold Justification
The 95% "On-spec" threshold represents the minimum potency at which PANACEA's dosing models remain valid without recalibration — below this level, the gap between modeled and actual effect size introduces unacceptable prediction error. The "Off-spec" floor at 85% was established after the 2023 potency drift incident, in which a 12-point decline in a sedation-agent batch produced a measurable 3-point rise in Dissent Level before the cause was identified.
Historical Context
APY was introduced as a batch-level quality metric when the Pharmacology division transitioned from single-agent to multi-agent production lines in 2021. Early batches exhibited high variance (88-99%) due to precursor-material inconsistencies. The adoption of PANACEA-guided synthesis optimization in 2023 narrowed the typical range to 94-98%. The metric remains sensitive to precursor supply disruptions, which have historically been the primary driver of off-spec readings.
Collection Method
R&D Pharmacology performs potency assays on every production batch at the point of release, comparing active-ingredient concentration and bioactivity against the design specification for each compound class. Results are logged to the Synaptic Data Fabric and flagged by PANACEA if they fall outside the expected range. For deployed agents, VITALNET environmental sensors and Halo biometric telemetry provide indirect potency validation through population-level effect monitoring.
Known Failure Modes
Bench-level potency assays may not reflect field-condition degradation caused by temperature excursions during Vector Fleet transport or storage, meaning a batch can pass QA at the lab but arrive at reduced efficacy. Multi-agent compound interactions are not fully captured by single-agent assay protocols, and emergent potency loss from formulation interactions has been observed in at least two documented cases. Environmental factors at the point of dispersal — UV exposure, water pH variability — can further reduce effective potency in ways the batch-level metric does not capture.